Haythem Y. Ali, MD

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses adjuvant studies with biosimilars in oncology.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses whether biosimilars can replace biologics in oncology.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the future of adjuvant treatment for patients with HER2-positive breast cancer.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses misconceptions about biosimilars in oncology.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the adjuvant treatment of patients with HER2-positive breast cancer.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the incorporation of biosimilars into cancer treatment.